Synthetic Bacteria Vaccine Against Antibiotics Resistant Bacteria
- Field
- Vaccine
- Patent
- IP01080
Key Problem and Market Opportunity
Some pseudaminic acid bacteria, such as Acinetobacter baumannii, Pseudomonas aeruginosa were listed as “priority list” by WHO. However there are a lack of effective antibiotics to treat them.
Key Advantages of the Technology
The underlying mechanism is a conjugation of pseudaminic acid which exits in pathogens to a carrier protein CRM197 to form anti-bacteria conjugate vaccines.
Benefits
- Promising protection efficacy
- Cost‑effective
Potential Product and Services
Vaccine for Pse carrying bacteria, e.g. Acinetobacter baumannii, Pseudomonas aeruginosa, and Campylobacter jejuni.
Development Status and IP Strength
Patents
- US provision application
IP Status
- Patent application submitted